Degrader battle sees Sanofi edged out for now
The French group was to have been first to report key Serd data this year, but has suffered delays as Roche and now Radius beat it to the punch.
The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Biotech’s important upcoming data
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
AACR 2021 preview – the early themes emerge
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
